Cisplatin and gemcitabine in non-small-cell lung cancer
Cisplatin and gemcitabine in non-small-cell lung cancer
复制标题
DOI：
10.1023/a:1008368624555
复制
发表时间：
1999-01-01
影响因子：
50.5
通讯作者：
Tabaro, G
中科院分区：
文献类型：
--
作者：
Cartei, G;Sacco, C;Tabaro, G
核苷类似物吉西他滨作为单药治疗转移性非小细胞肺癌（NSCLC）显示出活性，产生20%及以上的一致缓解率。由于其独特的作用机制及其与其他活性药物的非重叠毒性，吉西他滨是与其他细胞毒性药物联合试验的有吸引力的候选药物。在临床前模型中，顺铂-吉西他滨组合表明两种药物之间存在协同作用。在I-II期研究中，吉西他滨联合顺铂治疗III期和IV期NSCLC的缓解率高达54%。含吉西他滨的方案显示出良好的安全性-疗效特征，与NSCLC中使用的标准方案相比效果良好。这些初步结果必须通过比较含吉西他滨方案与NSCLC参考化疗方案的大型随机试验进行验证。
The nucleoside analogue, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC), producing consistent response rates of 20% and above. Because of its unique mechanism of action and its non-overlapping toxicity with other active agents, gemcitabine is an attractive candidate for trials in combination with other cytotoxic agents. In preclinical models, the cisplatin-gemcitabine combination suggested synergy between the two drugs. In phase I-II studies, response rates are as high as 54% when gemcitabine is combined with cisplatin, both in stage III and IV NSCLC. The gemcitabine-containing regimens showed a favourable safety-efficacy profile and compared well with standard regimens used in NSCLC. These preliminary results must be validated by large randomised trials comparing gemcitabine-containing regimens with NSCLC reference chemotherapy regimens.